Nymox Pharmaceutical (NASDAQ:NYMX) Stock Rating Upgraded by ValuEngine

ValuEngine upgraded shares of Nymox Pharmaceutical (NASDAQ:NYMX) from a hold rating to a buy rating in a report published on Thursday morning, ValuEngine reports.

Shares of NYMX stock traded down $0.03 during mid-day trading on Thursday, reaching $1.83. The stock had a trading volume of 1,705 shares, compared to its average volume of 94,677. Nymox Pharmaceutical has a 12-month low of $1.25 and a 12-month high of $3.27. The firm’s 50-day moving average is $1.65. The company has a quick ratio of 8.01, a current ratio of 8.04 and a debt-to-equity ratio of 0.03.

Nymox Pharmaceutical (NASDAQ:NYMX) last posted its quarterly earnings data on Wednesday, May 15th. The biopharmaceutical company reported ($0.04) EPS for the quarter. The company had revenue of $0.03 million for the quarter. Nymox Pharmaceutical had a negative return on equity of 175.82% and a negative net margin of 6,101.69%.

Institutional investors have recently bought and sold shares of the stock. Willow Creek Wealth Management Inc. increased its position in Nymox Pharmaceutical by 94.3% during the 1st quarter. Willow Creek Wealth Management Inc. now owns 34,124 shares of the biopharmaceutical company’s stock worth $67,000 after purchasing an additional 16,562 shares in the last quarter. Wedbush Securities Inc. increased its position in Nymox Pharmaceutical by 6.3% during the 2nd quarter. Wedbush Securities Inc. now owns 120,935 shares of the biopharmaceutical company’s stock worth $175,000 after purchasing an additional 7,200 shares in the last quarter. Geode Capital Management LLC increased its position in Nymox Pharmaceutical by 10.8% during the 4th quarter. Geode Capital Management LLC now owns 134,021 shares of the biopharmaceutical company’s stock worth $175,000 after purchasing an additional 13,103 shares in the last quarter. Bank of America Corp DE increased its position in Nymox Pharmaceutical by 130.1% during the 4th quarter. Bank of America Corp DE now owns 148,443 shares of the biopharmaceutical company’s stock worth $195,000 after purchasing an additional 83,925 shares in the last quarter. Finally, Northern Trust Corp increased its position in Nymox Pharmaceutical by 2.2% during the 4th quarter. Northern Trust Corp now owns 277,557 shares of the biopharmaceutical company’s stock worth $363,000 after purchasing an additional 6,026 shares in the last quarter. Hedge funds and other institutional investors own 5.66% of the company’s stock.

Nymox Pharmaceutical Company Profile

Nymox Pharmaceutical Corporation, a biopharmaceutical company, engages in the research and development of drugs for the aging population. It markets NicAlert and TobacAlert test strips that use urine or saliva to detect use of tobacco products. The company also offers AlzheimAlert, a proprietary urine assay that aids physicians in the diagnosis of Alzheimer's disease.

See Also: Trading Penny Stocks

To view ValuEngine’s full report, visit ValuEngine’s official website.

Receive News & Ratings for Nymox Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nymox Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.